Last $0.01 USD
Change Today -0.0004 / -3.12%
Volume 337.2K
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

bioheart inc (BHRT) Snapshot

Open
$0.01
Previous Close
$0.01
Day High
$0.01
Day Low
$0.01
52 Week High
03/6/14 - $0.08
52 Week Low
12/27/13 - $0.0089
Market Cap
7.2M
Average Volume 10 Days
779.9K
EPS TTM
$-0.0070
Shares Outstanding
578.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOHEART INC (BHRT)

Related News

No related news articles were found.

bioheart inc (BHRT) Related Businessweek News

No Related Businessweek News Found

bioheart inc (BHRT) Details

Bioheart, Inc., a development stage biotechnology company, focuses on the discovery, development, and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage, and degenerative diseases. Its lead product candidate is MyoCell, a clinical muscle-derived cell therapy that has completed Phase II-a study and populates regions of scar tissue within a patient’s heart with new living cells for improving cardiac function in chronic heart failure patients. The company also develops MyoCell SDF-1, an autologous cell therapy treatment for severe chronic damage to the heart and cells modified to express angiogenic factors; AdipoCell, an adipose cell therapy treatment for the management of progressive heart failure; and MyoCath, a disposable endoventricular catheter used for the delivery of biologic solutions to the myocardium. In addition, its preclinical stage product candidates include MyoCath II, which provides multidirectional cell injection, as well as is used for the delivery of biologic solutions to the myocardium. Bioheart, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

4 Employees
Last Reported Date: 11/21/14
Founded in 1999

bioheart inc (BHRT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bioheart inc (BHRT) Key Developments

Bioheart, Inc. Announces Positive 12 Month Preliminary Data From Phase I Angel Trial

Bioheart, Inc. released the preliminary 12 month data from its phase I ANGEL Trial. Fully funded by Bioheart, the trial is being conducted in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute (RMI). At the 12 month time point, patients are demonstrating a statistically significant average improvement in ejection fraction (EF) by echocardiogram. At the 3 month time point, 100% of the patients demonstrated either improvement or stayed the same. After 3 months, patients showed an average absolute improvement of 3 percentage points in EF. The patients continued to improve from 3 months to 6 months with a statistically significant average absolute improvement of 10 percentage points (p=0.01) and at the 12 month follow up patients showed this same level of improvement (p=0.01). This phase I study will provide necessary safety and preliminary efficacy of adipose derived stem cells (AdipoCell(TM)) in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months.

Bioheart Announces Opening of Laboratory and Clinic in South Africa

Bioheart, Inc. announced the opening the laboratory and clinic in South Africa. The facilities in South Africa opening will be able to provide cell therapies in the clinic as well as cell culture expansion and cryopreservation to local patients. Bioheart can multiply and preserve an individual's cells in sub-zero temperatures for future treatments as required. Bioheart's partnership will establish a critical relationship with the South African government and the joint venture will work closely with the Ministry of Health to make Bioheart protocols part of the standard of care for patients in South Africa and neighboring countries. Bioheart has provided the necessary training and expertise to transfer Bioheart therapies to the new facility. Bioheart will assume 49% ownership of the new entity. Dr. Walter Bell and his team will offer these therapies to the more than 51 million people living in South Africa as well as being a premier site for medical tourism.

Bioheart, Inc. Announces Earnings Results for the Year to Date Ended June 30, 2014

Bioheart, Inc. announced earnings results for the year to date ended June 30, 2014. For the period, the company product revenues are up from $24,321 to $819,606 comparing year to date of 2013 to year date of 2014. The revenues recognized to date are related to sales of MyoCath, patient treatments, AdipoCell systems and related supplies, and cell culturing and banking services. The company's net income increased to $226,034, as compared to a net loss of $1,269,231 in year to date of 2013, primarily resulting from gain on settlement of debt. The company has continued to take steps to streamline operational costs, decreasing its net cash used in operating activities by 54% from $1,095,000 in year to date of 2013 down to $507,000 in year to date of 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BHRT:US $0.01 USD -0.0004

BHRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cesca Therapeutics Inc $1.13 USD +0.04
Cytori Therapeutics Inc $0.48 USD -0.0141
International Stem Cell Corp $0.07 USD +0.0029
Nuo Therapeutics Inc $0.33 USD -0.0002
StemCells Inc $0.90 USD +0.0253
View Industry Companies
 

Industry Analysis

BHRT

Industry Average

Valuation BHRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOHEART INC, please visit www.bioheartinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.